Invasight develops first-in-class, protein-protein interaction inhibitors against invasive cancers. Our breakthrough technology, ACINDA accelerates drug discovery and enables precise design of small molecule inhibitors against specific proteins, which cause cancer cell invasion.

Products, services, technology

Our most advanced, first-in-class, protein-protein interaction inhibitor is F2i, an inhibitor of pro-invasive FGFR signalling. F2i is currently in 'pre-clinical' validation stage of drug development.

Cooperation possibilities

Strategic partnerships, joint development, integrated drug discovery

Location

Kreuzstrasse 17, 8008 Zürich, Switzerland

Facts & figures
  • Type of organization
    Public company
  • Year of foundation
    2020
  • Number of employees in Switzerland
    1-9